CMS admits no hard data on pharmacy payments
CMS has admitted that it has no hard evidence to back up deputyadministrator Leslie Norwalk's Congressional testimony thatpharmacies are being paid for Part D scripts on a 15-day billingcycle. Instead, Norwalk's assertion was based on informalinformation provided by Part D drug plans.
CMS admits no hard data on pharmacy payments
CMS has admitted that it has no hard evidence to back up deputy administrator Leslie Norwalk's Congressional testimony that pharmacies are being paid for Part D scripts on a 15-day billing cycle. Instead, Norwalk's assertion was based on informal information provided by Part D drug plans. The agency did not ask retail pharmacies about their experiences with slow payments from PBMs administering Part D plans.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
How Differences in Bispecific Therapies Impact Myeloma Treatment Operations
April 18th 2024According to Kirollos Hanna, PharmD, although similarities exist between bispecific therapies in the myeloma space, health care providers should take special note of practical differences and nuances associated with each when operationalizing them at their site of care.
